NICE accepts PAD treatment

Intermittent claudication can significantly impair mobility in people with PAD. | SCIENCE PHOTO LIBRARY
Intermittent claudication can significantly impair mobility in people with PAD. | SCIENCE PHOTO LIBRARY

Naftidrofuryl oxalate can now be prescribed on the NHS for the treatment of intermittent claudication caused by peripheral arterial disease (PAD). It may be used in patients for whom vasodilator therapy is considered appropriate.

Although naftidrofuryl oxalate does not halt the progression of PAD, it is believed to be the most clinically and cost effective treatment option in terms of improving maximum walking distance.

NICE rejected the other vasodilators cilostazol, pentoxifylline and inositol nicotinate for intermittent claudication in PAD on the grounds that they are not as clinically effective compared with placebo as naftidrofuryl oxalate.

View naftidrofuryl drug record

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Early emollient use does not prevent eczema in children

Early emollient use does not prevent eczema in children

Daily application of emollients in infancy is not effective...

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Macrolide prescribing in pregnancy linked to risk of birth defects

Macrolide prescribing in pregnancy linked to risk of birth defects

Researchers have called for caution when prescribing...

Drug shortages - live tracker

Drug shortages - live tracker

Added: Ativan and penicillamine.
Use our constantly...